| 21948233 |
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors
Heuckmann, JM,
Hölzel, M,
Sos, ML,
Heynck, S,
Balke-Want, H,
Koker, M,
Peifer, M,
Weiss, J,
Lovly, CM,
Grütter, C,
Rauh, D,
Pao, W,
Thomas, RK
|
Clin. Cancer Res. |
2011 |
| 18923525 |
Activating mutations in ALK provide a therapeutic target in neuroblastoma
George, RE,
Sanda, T,
Hanna, M,
Fröhling, S,
Luther, W,
Zhang, J,
Ahn, Y,
Zhou, W,
London, WB,
McGrady, P,
Xue, L,
Zozulya, S,
Gregor, VE,
Webb, TR,
Gray, NS,
Gilliland, DG,
Diller, L,
Greulich, H,
Morris, SW,
Meyerson, M,
Look, AT
|
Nature |
2008 |
| 27009859 |
TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors
Amin, AD,
Li, L,
Rajan, SS,
Gokhale, V,
Groysman, MJ,
Pongtornpipat, P,
Tapia, EO,
Wang, M,
Schatz, JH
|
Oncotarget |
2016 |
| 21791641 |
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
Sasaki, T,
Koivunen, J,
Ogino, A,
Yanagita, M,
Nikiforow, S,
Zheng, W,
Lathan, C,
Marcoux, JP,
Du, J,
Okuda, K,
Capelletti, M,
Shimamura, T,
Ercan, D,
Stumpfova, M,
Xiao, Y,
Weremowicz, S,
Butaney, M,
Heon, S,
Wilner, K,
Christensen, JG,
Eck, MJ,
Wong, KK,
Lindeman, N,
Gray, NS,
Rodig, SJ,
Jänne, PA
|
Cancer Res. |
2011 |